title: Radioimmunotherapy with alpha-particle emitting radionuclides.
abstract: An important consideration in the development of effective strategies for radioimmunotherapy is the nature of the radiation emitted by the radionuclide. Radionuclides decaying by the emission of alpha-particles offer the possibility of matching the cell specific reactivity of monoclonal antibodies with radiation with a range of only a few cell diameters. Furthermore, alpha-particles have important biological advantages compared with external beam radiation and beta-particles including a higher biological effectiveness, which is nearly independent of oxygen concentration, dose rate and cell cycle position. In this review, the clinical settings most likely to benefit from alpha-particle radioimmunotherapy will be discussed. The current status of preclinical and clinical research with antibodies labeled with 3 promising alpha-particle emitting radionuclides - (213)Bi, (225)Ac, and (211)At - also will be summarized.
authors.affiliation: Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA. zalut001@mc.duke.edu
authors.forename: M R
authors.initials: MR
authors.lastname: Zalutsky
authors.forename: O R
authors.initials: OR
authors.lastname: Pozzi
mesh_terms: D000186:Actinium / Q000627:therapeutic use*; D000512:Alpha Particles / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001246:Astatine / Q000627:therapeutic use*; D001729:Bismuth / Q000627:therapeutic use*; D006801:Humans; D007554:Isotopes / Q000627:therapeutic use; D009369:Neoplasms / Q000532:radiotherapy*; D010818:Practice Patterns, Physicians'; D016499:Radioimmunotherapy / Q000379:methods*; D011868:Radioisotopes / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007554:Isotopes; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D000186:Actinium; D001729:Bismuth; D001246:Astatine